167 related articles for article (PubMed ID: 2786751)
21. Improved pharmacokinetics and tumor localization of immunotoxins constructed with the Mr 30,000 form of ricin A chain.
Trown PW; Reardan DT; Carroll SF; Stoudemire JB; Kawahata RT
Cancer Res; 1991 Aug; 51(16):4219-25. PubMed ID: 1868442
[TBL] [Abstract][Full Text] [Related]
22. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of human tumor growth by intraperitoneal immunotoxins in nude mice.
Marks A; Ettenson D; Bjorn MJ; Lei M; Baumal R
Cancer Res; 1990 Jan; 50(2):288-92. PubMed ID: 2295069
[TBL] [Abstract][Full Text] [Related]
24. Whole ricin and recombinant ricin A chain idiotype-specific immunotoxins for therapy of the guinea pig L2C B cell leukemia.
Gregg EO; Bridges SH; Youle RJ; Longo DL; Houston LL; Glennie MJ; Stevenson FK; Green I
J Immunol; 1987 Jun; 138(12):4502-8. PubMed ID: 3495593
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the pharmacokinetics and hepatotoxic effects of saporin and ricin A-chain immunotoxins on murine liver parenchymal cells.
Blakey DC; Skilleter DN; Price RJ; Watson GJ; Hart LI; Newell DR; Thorpe PE
Cancer Res; 1988 Dec; 48(24 Pt 1):7072-8. PubMed ID: 3263899
[TBL] [Abstract][Full Text] [Related]
26. Phase I trial of recombinant macrophage colony-stimulating factor and recombinant gamma-interferon: toxicity, monocytosis, and clinical effects.
Weiner LM; Li W; Holmes M; Catalano RB; Dovnarsky M; Padavic K; Alpaugh RK
Cancer Res; 1994 Aug; 54(15):4084-90. PubMed ID: 8033141
[TBL] [Abstract][Full Text] [Related]
27. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
[TBL] [Abstract][Full Text] [Related]
28. Antimelanoma monoclonal antibody-ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: results of a phase II trial.
Oratz R; Speyer JL; Wernz JC; Hochster H; Meyers M; Mischak R; Spitler LE
J Biol Response Mod; 1990 Aug; 9(4):345-54. PubMed ID: 2395000
[TBL] [Abstract][Full Text] [Related]
29. Recombinant ricin A chain conjugated to monoclonal antibodies: improved tumor cell inhibition in the presence of lysosomotropic compounds.
Ramakrishnan S; Bjorn MJ; Houston LL
Cancer Res; 1989 Feb; 49(3):613-7. PubMed ID: 2783383
[TBL] [Abstract][Full Text] [Related]
30. Toxicity and immunogenicity of monoclonal antimelanoma antibody-ricin A chain immunotoxin in rats.
Harkonen S; Stoudemire J; Mischak R; Spitler LE; Lopez H; Scannon P
Cancer Res; 1987 Mar; 47(5):1377-82. PubMed ID: 3493064
[TBL] [Abstract][Full Text] [Related]
31. A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia.
Hertler AA; Schlossman DM; Borowitz MJ; Laurent G; Jansen FK; Schmidt C; Frankel AE
J Biol Response Mod; 1988 Feb; 7(1):97-113. PubMed ID: 3373237
[TBL] [Abstract][Full Text] [Related]
32. Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin.
Lynch TJ; Lambert JM; Coral F; Shefner J; Wen P; Blattler WA; Collinson AR; Ariniello PD; Braman G; Cook S; Esseltine D; Elias A; Skarin A; Ritz J
J Clin Oncol; 1997 Feb; 15(2):723-34. PubMed ID: 9053498
[TBL] [Abstract][Full Text] [Related]
33. Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model.
Weil-Hillman G; Runge W; Jansen FK; Vallera DA
Cancer Res; 1985 Mar; 45(3):1328-36. PubMed ID: 3971376
[TBL] [Abstract][Full Text] [Related]
34. Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study.
Rupp U; Schoendorf-Holland E; Eichbaum M; Schuetz F; Lauschner I; Schmidt P; Staab A; Hanft G; Huober J; Sinn HP; Sohn C; Schneeweiss A
Anticancer Drugs; 2007 Apr; 18(4):477-85. PubMed ID: 17351401
[TBL] [Abstract][Full Text] [Related]
35. An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors.
Scott CF; Goldmacher VS; Lambert JM; Jackson JV; McIntyre GD
J Natl Cancer Inst; 1987 Nov; 79(5):1163-72. PubMed ID: 3500356
[TBL] [Abstract][Full Text] [Related]
36. Efficient transplantation of human non-T-leukemia cells into nude mice and induction of complete regression of the transplanted distinct tumors by ricin A-chain conjugates of monoclonal antibodies SN5 and SN6.
Hara H; Luo Y; Haruta Y; Seon BK
Cancer Res; 1988 Aug; 48(16):4673-80. PubMed ID: 2969282
[TBL] [Abstract][Full Text] [Related]
37. Intraventricular immunotoxin therapy for leptomeningeal neoplasia.
Laske DW; Muraszko KM; Oldfield EH; DeVroom HL; Sung C; Dedrick RL; Simon TR; Colandrea J; Copeland C; Katz D; Greenfield L; Groves ES; Houston LL; Youle RJ
Neurosurgery; 1997 Nov; 41(5):1039-49; discussion 1049-51. PubMed ID: 9361057
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of anti-CD5 ricin A chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow transplantation.
Przepiorka D; LeMaistre CF; Huh YO; Luna M; Saria EA; Brown CT; Champlin RE
Ther Immunol; 1994 Apr; 1(2):77-82. PubMed ID: 7584486
[TBL] [Abstract][Full Text] [Related]
39. Phase I study of monoclonal antibody-ricin A chain immunoconjugate Xomazyme-791 in patients with metastatic colon cancer.
LoRusso PM; Lomen PL; Redman BG; Poplin E; Bander JJ; Valdivieso M
Am J Clin Oncol; 1995 Aug; 18(4):307-12. PubMed ID: 7625372
[TBL] [Abstract][Full Text] [Related]
40. The effects of cyclophosphamide on the toxicity and immunogenicity of ricin A chain immunotoxin in rats.
Stoudemire JB; Mischak R; Foxall C; Harkonen WS; Del Rio M; Spitler LE
Mol Biother; 1990 Sep; 2(3):179-84. PubMed ID: 2222902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
